Меню
Набор скоро начнётся NCT07592806

CRISTEL Study: Monitoring of Pregnancies in Women After Solid Organ Transplantation

Без фазы С лечением Surgical Operation With Transplant of Whole Organ

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Blood sample.
Кому может быть актуально
Состояния в реестре: Surgical Operation With Transplant of Whole Organ. Базовые параметры: 18 лет — 48 лет · Женщины.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Список центров уточняется — проверьте первичный протокол.
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Обзор

The objective of this research is to obtain standardized and independent data on the number of pregnancies occurring in France and their follow-up up to 1 year postpartum (or post-pregnancy termination). This study will then aim to describe the clinical characteristics and maternal and perinatal outcomes of pregnancies in this specific population. These data will enable the dissemination of clear and up-to-date information to the medical community, thus contributing to better patient counseling and, more broadly, to couples. They will also serve to issue recommendations to optimize the planning and follow-up of pregnancies in women with solid organ transplants. Finally, this initiative aims to promote clinical research on pregnancies.

Подробное описание

According to North American and Australian registries, pregnancy is both a joyful and high-risk event for women who have received a solid organ transplant. Typically, a transplanted woman has a probability comparable to that of the general population of giving birth to a live infant, but she is likely to deliver prematurely (median gestational age: 32 weeks), to have a growth-restricted baby (median birth weight around 2.3 kg), and often in a context of preeclampsia (in at least 30% of cases)(1).

Today, these are the data shared with patients planning a pregnancy, despite uncertainty as to their accuracy and applicability in France or even Europe.

Among the unknowns that remain despite these registry data, the following should be noted:

Uncertainty about the level of pregnancy planning in this specific context: What proportion of women of childbearing age have been informed of the possibility of becoming pregnant, of the associated risks, and of necessary precautions (e.g., stopping mycophenolate mofetil at least 6 weeks before conception);

Variability in the information provided from one center to another, due to the absence of a national, consensus-based document addressing fertility and contraception in the post-transplantation setting;

Monitoring frequency specific to the graft, especially regarding exposure to immunosuppressive drugs (and consequently actual exposure to calcineurin inhibitors, the cornerstone of anti-rejection therapy, whose residual blood concentration varies from the second trimester onward)(2);

The true risk of preeclampsia, at a time when diagnosis can be refined by measuring levels of placental-derived anti-angiogenic factors in maternal serum (sFlt-1/PlGF ratio)(3), and by uterine artery Doppler;

The incidence of de novo anti-HLA immunization (HLA antigens expressed by the fetus and inherited from the father), which can now be assessed using the Luminex technique(4);

Maternal morbidity: What is the impact of pregnancy on graft function? Conversely, how does renal function influence pregnancy outcomes, regardless of the transplanted organ?

Infant morbidity in the short and medium term.

To establish these data and to provide accurate information to patients, we aim to conduct a study among pregnant women who have undergone solid organ transplantation (kidney, heart, lung, liver, or pancreas). The objective of this research is to collect standardized and independent data on the number of pregnancies occurring in France and to monitor them up to one year postpartum (or after pregnancy termination).

The study will then aim to describe the clinical characteristics and maternal and perinatal outcomes of pregnancies in this specific population. These data will help disseminate clear and up-to-date information to the medical community, thus improving patient counseling and, more broadly, support for couples. They will also serve to develop recommendations to optimize the planning and management of pregnancies in women with solid organ transplants.

Finally, this initiative aims to promote clinical research on pregnancy in the context of transplantation, particularly through clinical trials and the development of biobanks.

Вмешательства

  • Другое Blood sample
    Two optional (non-mandatory) biological samples may be collected as part of this study: A 2 mL venous blood sample may be taken during a routine prenatal follow-up visit (around 30 weeks of gestation) in order to analyze the preeclampsia biomarker (sFlt-1/PlGF ratio), whenever preeclampsia is suspected. A 5 mL sample from cord blood may be collected after delivery to analyze, in the newborn, the complete blood count, white blood cell differential, lymphocyte phenotyping (T CD3+, CD19+CD20+, an

Первичные конечные точки

  • The primary outcome is the annual incidence of conception in the population of women with solid organ transplants (i.e., included in the study). [Срок оценки: Annually over the 10-year study period]
Вторичные конечные точки (12)
  • Rate of preeclampsia [Срок оценки: Through study completion, an average of 1 year]
  • Trajectory of estimated glomerular filtration rate (eGFR, in mL/min/1.73 m²); [Срок оценки: 3 months and 12 months postopartum]
  • Live birth rate among transplanted mothers from the onset of pregnancy. [Срок оценки: through study completion, an average of 1 year]
  • Trajectory of serum creatinine levels [Срок оценки: During pregnancy (up to 40 weeks if gestation)]
  • Rate of maternal complications before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage) [Срок оценки: During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth]
  • Mode of delivery (spontaneous labor, induced labor, planned cesarean section, or emergency cesarean section); gestational age at delivery (in weeks of gestation); proportion of gestational hypertension and preeclampsia. [Срок оценки: Day of delivery: Perioperative/Periprocedural]
  • Birth weight of the newborn (in grams) [Срок оценки: day of delivery]
  • Rate of spontaneous miscarriage [Срок оценки: Through study completion, an average of 1 year]
  • Rate of cesarean section [Срок оценки: Through study completion, an average of 1 year]
  • Rate of prematurity [Срок оценки: Through study completion, an average of 1 year]
  • Rate of intrauterine growth restriction [Срок оценки: Through study completion, an average of 1 year]
  • the duration of hospital stay for both the mother and the newborn [Срок оценки: Through study completion, an average of 1 year]

Критерии участия

Критерии включения

  • Female patient aged 18 years or older and of childbearing age
  • Has received a solid organ transplant, either isolated or combined (heart, liver, lung, pancreas, kidney)
  • Has a positive blood beta-hCG test result > 5 IU/L ("positive")
  • Has signed an informed consent form
  • Affiliated with a health insurance plan

Критерии исключения

  • Patient deprived of liberty or under legal guardianship
  • Patient refuses to participate in the study

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Не применимо
Модель
Одна группа
Маскирование
Открытое
Основная цель
Скрининг

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07592806 · 2023_0004

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗